Details

Autor(en) / Beteiligte

• Lee, Sung-Eun
• Lim, Ji-Young
• Ryu, Da-Bin
• Kim, Tae Woo
• Park, Sung Soo
• Jeon, Young-Woo
• Yoon, Jae-Ho
• Cho, Byung-Sik
• Eom, Ki-Seong
• Kim, Yoo-Jin
• Kim, Hee-Je
• Lee, Seok
• Cho, Seok-Goo
• Kim, Dong-Wook
• Lee, Jong Wook
• Min, Chang-Ki

Titel

Low frequency of CD3+CD4+CD161+ T cells correlates with the occurrence of infections in refractory/relapsed multiple myeloma patients receiving lenalidomide plus low-dose dexamethasone treatment

Ist Teil von

• Annals of hematology, 2018-11, Vol.97 (11), p.2163-2171

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2018

Quelle

MEDLINE

Beschreibungen/Notizen

• The aim of this study was to explore the predictive implications of the composition of immune cell populations prior to lenalidomide plus high-dose dexamethasone (Len-Dex) initiation for the occurrence of infections. We prospectively examined immune cell populations in peripheral blood taken at baseline of lenalidomide plus low-dose dexamethasone (Len-dex) therapy and reviewed clinical and microbiology records in 90 patients with refractory/relapsed multiple myeloma (RRMM). Risk factors for infection were analyzed using logistic regression. During a median of 11 cycles of Len-dex treatment, 52 (57.8%) patients experienced at least 1 infection episode. Of a total of 92 episodes of infection, 58 (63%) episodes were clinically defined, 29 (31.5%) episodes were microbiologically defined, and 5 (5.4%) episodes were fever of unknown origin. Severe episodes were more frequently observed during the first 3 cycles. After adjusting for risk factors for infection based on univariate analyses, multivariate analyses showed that lower Hb (< 10 g/dL) was a clinically independent factor associated with occurrence of infections. Lower frequency ( P  = 0.044) and absolute count ( P  = 0.014) of circulating CD3 + CD4 + CD161 + cells prior to Len-dex treatment were also associated with the occurrence of infection, especially during the first 3 cycles of Len-dex therapy. In addition to several clinical predictive factors, we found that CD3 + CD4 + CD161 + cells may provide additional information for predicting the occurrence of infection in the early period of Len-dex therapy.